Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549907
Status:
RECRUITING
Last Update Posted:
None
First Post:
2023-11-10
Brief Title:
A Biomarker Exploratory Study of Dual Blockade of PD1PDL1 and CTLA4 and Anti-angiogenic Therapy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Biomarker Exploratory Study of Efficacy and Prognosis of Dual Blockade of PD1PDL1 and CTLA4 in Combination of Anti-angiogenic Treatment in MSS Metastatic Colorectal Cancers and MSI Solid Tumors Refractory to PD1PDL1 Antibody Monotherapy
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center prospective exploratory research aiming to identify clinical characteristics and biomarkers associated with the therapeutic effects of dual PD1PDL1 and CTLA4 blockade plus anti-angiogenic therapy and investigate MR image characteristics during treatment in patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1PD-L1 antibody monotherapy
Detailed Description:
This study is a single-center prospective exploratory research Patients with MSS metastatic colorectal cancer and MSI solid tumors resistant to PD-1PD-L1 antibody monotherapy who are treated with dual PD1PDL1 and CTLA4 blockade combined with anti-angiogenic therapy in the Department of Gastrointestinal Oncology of Peking University Cancer Hospital will be enrolled Their clinical-pathological features and specimens will be collected at baseline at each tumor assessment point and at disease progression
This study aims to identify clinical characteristics and biomarkers associated with the therapeutic effects through multi-omics approaches and to investigate MR image characteristics during treatment Samples include tissue blood urine and stool and multi-omics approaches include single-cell sequencing spatial transcriptome sequencing macro transcriptome sequencing whole exome sequencing microproteomics immunohistochemistry and multiplex fluorescence immunohistochemistry
This study aims to identify clinical characteristics and biomarkers associated with the therapeutic effects through multi-omics approaches and to investigate MR image characteristics during treatment Samples include tissue blood urine and stool and multi-omics approaches include single-cell sequencing spatial transcriptome sequencing macro transcriptome sequencing whole exome sequencing microproteomics immunohistochemistry and multiplex fluorescence immunohistochemistry
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None